Investigation announced for Investors in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) over possible Violations of Securities Laws

An investigation was announced over potential securities laws violations by BridgeBio Pharma, Inc. in connection with certain financial statements.

Investors who purchased shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by BridgeBio Pharma, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Palo Alto, CA based BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

On June 5, 2024, BridgeBio Pharma, Inc. issued a press release "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile." Despite the study's ostensibly positive results, a Pipe Sandler analyst compared infigratinib to Voxzogo, an already approved drug produced by BioMarin Pharmaceutical Inc., opining that BridgeBio's drug "does not appear well-differentiated from Voxzogo" and that "without any clinical differentiation, we see the competitive threat as mixed."

Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) declined from $31.16 per share on May 16, 2024, to $26.53 per share on June 10, 2024.

Those who purchased shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.